Cancer Immunology, Immunotherapy

, Volume 32, Issue 1, pp 55–61 | Cite as

The in vitro development of cytotoxicity in response to granulocyte/macrophage-colony-stimulating factor or interferon γ in the peripheral blood monocytes of patients with solid tumors: Modulation by arachidonic acid metabolic inhibitors

  • Donald P. Braun
  • Kalliopi P. Siziopikou
  • Larry C Casey
  • Jules E. Harris
Original articles


The capacity of granulocyte/macrophage-colony-stimulating factor (GM-CSF) and interferon γ (IFN γ) to elicit monocyte cytotoxicity in vitro in the peripheral blood monocytes of patients with solid tumors was investigated. The cytotoxicity elicited by IFN γ was significantly reduced in cancer patient monocytes compared to normal monocytes. The cytotoxicity elicited by GM-CSF, however, was comparable between cancer patient monocytes and normal monocytes, but was lower than that induced by IFN γ. Indomethacin, a cyclooxygenase inhibitor, significantly augmented IFN γ-elicited cytotoxicity in cancer patient monocytes, but not in normal monocytes. In contrast, indomethacin augmented GM-CSF-elicited cytotoxicity in both cancer patient monocytes and normal monocytes. Nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor, was found to suppress cytotoxicity in response to IFN γ and GM-CSF in both cancer patient monocytes and normal monocytes. The addition of leukotrienes to NDGA-treated cultures restored the development of cytotoxicity. Thus there are differences in the in vitro response of cancer patient monocytes and normal monocytes to distinct biological activators. Furthermore, these responses can be manipulated by agents that modulate arachidonic acid metabolism.


Cancer Patient Cancer Research Biological Activator Interferon Solid Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bass DA, Thomas MJ, Goetzl EJ, DeChatelet LR, McCall CE (1981) Lipoxygenase derived products of arachidonic acid mediate stimulation of hexose uptake in human polymorphonuclear leukocytes. Biochem Biophys Res Commun 100: 1Google Scholar
  2. 2.
    Berlinger NT (1984) Deficient immunity in head and neck cancer due to excessive monocyte production of prostaglandins. Laryngoscope 94: 1407Google Scholar
  3. 3.
    Bloom ET, Babbitt JT (1985) Monocyte-mediated augmentation of human natural cell-mediated cytotoxicity. Cell Immunol 91: 21Google Scholar
  4. 4.
    Bokoch GM, Reed PW (1979) Inhibition of the neutrophil oxidative response to a chemotactic peptide by inhibitors of arachidonic acid oxygenation. Biochem Biophys Res Commun 90: 481Google Scholar
  5. 5.
    Borasketi D, Ansini S, Tagliabue A (1984) Interferon-gamma reduces macrophage-suppressive activity by inhibiting prostaglandin E2 release and inducing interleukin productions. J Immunol 133: 764Google Scholar
  6. 6.
    Braun DP, Harris JE, Rubenstein M (1984) Relationship of arachidonic acid metabolism to indomethacin-sensitive immunoregulatory function and lymphocyte PGE sensitivity in peripheral blood mononuclear cells of disseminated solid tumor cancer patients. J Immunopharmacol 6: 227Google Scholar
  7. 7.
    Braun DP, Kessler H, Falk L, Paul D, Harris JE, Blaauw B, Landay AL (1988) Monocyte functional studies in asymptomatic HIV-infected individuals. J Clin Immunol 8: 486Google Scholar
  8. 8.
    Cameron DJ, Stromberg BV (1984) The ability of macrophages from head and neck cancer patients to kill tumor cells. Effect of prostaglandin inhibitors on cytotoxicity. Cancer 54: 2403Google Scholar
  9. 9.
    Colotta F, Bersani L, Lazzarin A, Poli G, Mantovani A (1985) Rapid killing of actinomycin D-treated tumor cells by human monocytes. II. Cytotoxicity is independet of secretion of reactive oxygen intermediates and is suppressed by protease inhibitors. J Immunol 134: 3524Google Scholar
  10. 10.
    DeBaetselier P, Kapon A, Katzav S, Tzehoval E, Dekegel D, Segal S, Feldman M (1985) Selecting, accelerating and suppressing interactions between macrophages and tumor cells. Invasion Metastasis 5: 106Google Scholar
  11. 11.
    DeBoer KP, Braun DP, Harris JE (1982) Natural cytotoxicity and antibody-dependent cytotoxicity in solid tumor cancer patients: regulation by adherent cells. Clin Immunol Immunopathol 23: 133Google Scholar
  12. 12.
    Engert A, Gabrilove JL, Welk K et al. (1987) Cell surface marker analysis on peripheral blood mononuclear cells (PBMC) from patients with advanced malignancy treated with recombinant tumor necrosis factor alpha (rTNF). Proc Am Assoc Cancer Res 28: 187Google Scholar
  13. 13.
    Fidler IJ, Kleinerman ES (1984) Lymphokine-activated human blood monocytes destroy tumor cells but not normal cells under cocultivation conditions. J Clin Oncol 2: 937Google Scholar
  14. 14.
    Gabrilove JL, Starnes A, Begas A, Casper E et al. (1987) A phase I study of intravenously administered recombinant tumor necrosis factor alpha in patients with advanced cancer. Proc Am Soc Clin Oncol 6: 247Google Scholar
  15. 15.
    Gerrard TL, Terz JJ, Kaplan AM (1980) Cytotoxicity to tumor cells of monocytes from normal individuals and cancer patients. Int J Cancer 26: 585Google Scholar
  16. 16.
    Hancock WW, Pleau ME, Kobzik L (1988) Recombinant granulocyte-macrophage colony-stimulating factor down-regulates expression of IL-2 receptor on human mononuclear phagocytes by induction of prostaglandine. J Immunol 140: 3021Google Scholar
  17. 17.
    Huddlestone JR, Merigan TC Jr, Oldstone MBA (1979) Induction and kinetics of natural killer cells in humans following interferon therapy. Nature 282: 417Google Scholar
  18. 18.
    Keisari Y, Flescher E, Geva I (1984) Macrophage oxidative burse and related cytotoxicity. I. Differential activation by tumor-promoting and non-tumor-promoting phorbol esters. Int J Cancer 34: 845Google Scholar
  19. 19.
    Kleinerman ES, Knowles RD, Lachman LB, Gutterman JU (1988) Effect of recombinant granulocyte/macrophage colony-stimulating factor on human monocyte activity in vitro following intravenous administration. Cancer Res 48: 2604Google Scholar
  20. 20.
    Koren HS, Leung KH (1982) Modulation of human NK cells by interferon and prostaglandin E2. Mol Immunol 19: 1341Google Scholar
  21. 21.
    Krown SE, Real FX, Cunningham-Rundles S, Myskowski PL, Koziner B, Fein S, Mittelman A, Oettgen HF, Safai B (1983) Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. N Engl J Med 308: 1071Google Scholar
  22. 22.
    Kunkel SL, Spengler M, May MA, Spengler R, Larrick J, Remick D (1988) Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression. J Biol Chem 263: 5380Google Scholar
  23. 23.
    Kurland JI, Bockman RS, Broxmeyer HE, Moore MAS (1978) Limitation of excessive myelopoiesis by the intrinsic modulation of macrophage-derived prostaglandin E. Science 199: 522Google Scholar
  24. 24.
    Laszlo J, Huang AT, Brenckman WD, Jeffs C, Koren H, Cianciolo G, Metzgar R, Cashdollar W, Cox E, Buckley CE III, Tso CY, Lucas VS Jr (1983) Phase I study of pharmacological and immunological effects of human lymphoblastoid interferon given to patients with cancer. Cancer Res 43: 4458Google Scholar
  25. 25.
    Mantovani A, Polentarutti N, Peri G, Shavit ZB, Vecchi A, Bolis G, Mangioni C (1980) Cytotoxicity on tumor cells of peripheral blood monocytes and tumor-associated macrophages in patients with ascites ovarian tumors J Natl Cancer Inst 64: 1307Google Scholar
  26. 26.
    Mavier P, Edgington RS (1984) Human monocyte-mediated tumor cytotoxicity. I. Demonstration of an oxygen-dependent myeloperoxidase-independent mechanism. J Immunol 132: 1980Google Scholar
  27. 27.
    McCormick KJ, Panje WR (1986) Indomethacin-induced augmentation of lymphoproliferative responses in patients with head and neck cancer. Cancer Immunol Immunother 21: 226Google Scholar
  28. 28.
    McMannis JD, Fisher RI, Creekmore SP, Braun DP, Harris JE, Ellis TM (1988) In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine activated killer effector cells from cancer patients receiving recombinant IL-2. J Immunol 140: 1335Google Scholar
  29. 29.
    Monick M, Glazier J, Hunninghake GW (1987) Human alveolar macrophages suppress interleukin-1 (IL-1) activity via the secretion of prostaglandin E2. Am Rev Respir Dis 135: 72Google Scholar
  30. 30.
    O'Flaherty JT, Showell HJ, Ward PA, Becker EL (1979) A possible role of arachidonic acid in human neutrophil aggregation and degranulation. Am J Pathol 96: 799Google Scholar
  31. 31.
    Polverini PJ, Leibovich SJ (1984) Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab Invest 51: 635Google Scholar
  32. 32.
    Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RA, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889Google Scholar
  33. 33.
    Rosenthal NS, Hank JA, Kohler PC, Minkoff DZ, Moore KH, Bechhofer R, Hong R, Storer B, Sondel PM (1988) The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2. J Biol Response Mod 7: 123Google Scholar
  34. 34.
    Roth MD, Golub SH (1988) Inhibition of lymphokine-activated killer cell function by alveolar macrophages. Chest 94: 44SGoogle Scholar
  35. 35.
    Russell SW, Pace JL (1984) Gamma interferon interfers with the negative regulation of macrophage activation by prostaglandin E2. Mol Immunol 21: 249Google Scholar
  36. 36.
    Schinkein HA (1986) Prostaglandin E and thromboxane B2 release by PMA-induced U937 cells in response to C3b. J Leukocyte Biol 39: 511Google Scholar
  37. 37.
    Schulof RS, Michitsch RW, Livingston PO, Gupta S (1981) Monocyte-mediated suppression of lymphocyte cytotoxic activity for culture autologous melanoma cells. Cell Immunol 57: 529Google Scholar
  38. 38.
    Showel HJ, Naccache P, Sha'afi RI, Becker EL (1980) Inhibition of rabbit neutrophil lysosomal enzyme secretion, nonstimulated and chemotactic factor stimulated locomotion by nordihydroguaiaretic acid. Life Sci 27: 421Google Scholar
  39. 39.
    Tilden AB, Balch CM (1982) A comparison of PGE2 effects on human suppressor cell function and on interleukin-2 function. J Immunol 129: 2469Google Scholar
  40. 40.
    Walenga RW, Showell HJ, Feinstein MB Becker EL (1980) Parallel inhibition of neutrophil arachidonic acid metabolism and lysosomal enzyme secretion by nordihydroguaiaretic acid. Life Sci 27: 1047Google Scholar
  41. 41.
    Wanebo HJ, Riley T, Katz D, Pace RC, Johns ME, Cantrell RW (1988) Indomethacin sensitive suppressor-cell activity in head and neck cancer patients. The role of the adherent mononuclear cell. Cancer 61: 462Google Scholar
  42. 42.
    Wiederhold MD, Ondrey F, Anderson KM, Braun DP, Harris JE (1988) Synthesis of eicosanoids by gamma interferon differentiated U937 cells. Clin Physiol Biochem 6: 21Google Scholar
  43. 43.
    Yanagawa E, Yasumoto K, Manabe H, Nagano N, Hirota N, Ohta M, Hattori T, Nomoto K, Azuma I, Yamamura Y (1979) Cytostatic activity of peripheral blood monocytes against bronchogenic carcinoma cells in patients with lung cancer. Gann 70: 533Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • Donald P. Braun
    • 1
    • 3
  • Kalliopi P. Siziopikou
    • 1
    • 3
  • Larry C Casey
    • 2
  • Jules E. Harris
    • 1
    • 3
  1. 1.Section of Medical OncologyRush-Presbyterian-St. Luke's Medical CenterChicagoUSA
  2. 2.Section of Pulmonary Medicine, Department of Internal MedicineRush-Presbyterian-St. Luke's Medical CenterChicagoUSA
  3. 3.Department of Immunology/MicrobiologyRush-Presbyterian-St. Luke's Medical CenterChicagoUSA

Personalised recommendations